GRAMD1B Protein - GRAM Domain Containing 1B

GRAMD1B Protein - GRAM Domain Containing 1B

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GRAMD1B Protein - GRAM Domain Containing 1B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GRAMD1B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GRAMD1B - GRAM Domain Containing 1B</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GRAMD1B" target="_blank">Search UniProt</a></td>
</tr>
</table>

GRAMD1B (GRAM Domain Containing 1B, also known as VIPAR) is a 559-amino acid protein encoded by the GRAMD1B gene (NCBI Gene: 54550). It belongs to the GRAMD1 protein family, which includes GRAMD1A and GRAMD1C (also known as Sphingomyelin Phosphodiesterase 4D-Interacting Protein or SMPD4IP). GRAMD1B is a multi-domain protein localized primarily to the endoplasmic reticulum (ER) and endosomes, where it participates in lipid metabolism, autophagy regulation, and cellular stress responses. While initially characterized for its role in autosomal recessive spastic paraplegia, emerging research suggests GRAMD1B may have broader functions in neuronal homeostasis and neurodegenerative disease pathogenesis.
title: GRAMD1B Protein

GRAMD1B Protein - GRAM Domain Containing 1B

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GRAMD1B Protein - GRAM Domain Containing 1B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GRAMD1B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GRAMD1B - GRAM Domain Containing 1B</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GRAMD1B" target="_blank">Search UniProt</a></td>
</tr>
</table>

GRAMD1B (GRAM Domain Containing 1B, also known as VIPAR) is a 559-amino acid protein encoded by the GRAMD1B gene (NCBI Gene: 54550). It belongs to the GRAMD1 protein family, which includes GRAMD1A and GRAMD1C (also known as Sphingomyelin Phosphodiesterase 4D-Interacting Protein or SMPD4IP). GRAMD1B is a multi-domain protein localized primarily to the endoplasmic reticulum (ER) and endosomes, where it participates in lipid metabolism, autophagy regulation, and cellular stress responses. While initially characterized for its role in autosomal recessive spastic paraplegia, emerging research suggests GRAMD1B may have broader functions in neuronal homeostasis and neurodegenerative disease pathogenesis.
title: GRAMD1B Protein
.infobox.infix-protein
; Protein Name
: GRAM Domain Containing 1B
; Gene Symbol
: [GRAMD1B](/proteins/gramd1b-protein)
; UniProt ID
: [Q9Y3D6](https://www.uniprot.org/uniprotkb/Q9Y3D6)
; Molecular Weight
: ~65 kDa
; Amino Acids
: 559
; Subcellular Localization
: Endoplasmic reticulum, endosomes, Golgi apparatus
; Protein Family
: GRAMD1 family (GRAM domain-containing proteins)
; Alternative Names
: VIPAR, VPS33A-interacting protein (VIPAR)

Overview

GRAMD1B is a member of the GRAM (Glucosyltransferases, Rab-like GTPase activators, and Myotubularins) domain-containing protein family, which shares homology with the lipid phosphatase domain of myotubularins[@begley2013]. Unlike classical GRAM domain proteins, GRAMD1B contains additional functional domains including an N-terminal GRAM domain, a central StAR-related lipid transfer (START) domain, and a C-terminal hydrophobic transmembrane region. This unique domain architecture enables GRAMD1B to function as a lipid transfer protein and membrane scaffolding molecule[@gomes2019].

The protein is widely expressed in human tissues, with highest expression in brain, testis, and kidney. Within the brain, GRAMD1B is expressed in [neurons](/entities/neurons) and glial cells, including [astrocytes](/entities/astrocytes) and [microglia](/entities/microglia), suggesting roles in both neuronal homeostasis and neuroimmune signaling[@uhlen2015].

Key Functions of GRAMD1B

• Autophagosome biogenesis and maturation: GRAMD1B interacts with the HOPS (Homotypic fusion and vacuole protein sorting) complex and VPS33A to regulate autophagosome-lysosome fusion[@mcgough2018]
• Endolysosomal trafficking: Controls trafficking between endosomes and lysosomes through interactions with the retromer complex[@cullen2009]
• Lipid homeostasis: The START domain facilitates transfer of sterols and phospholipids between membrane compartments[@iaea2017]
• Cellular stress responses: Upregulated during ER stress and participates in the [unfolded protein response](/entities/unfolded-protein-response) (UPR)[@kimata2017]

Domain Structure

N-terminal GRAM Domain (1-150 amino acids)

The N-terminal GRAM domain serves as a phosphoinositide-binding module that targets GRAMD1B to specific membrane compartments[@mao2019]:

• Binds specifically to phosphatidylinositol-3-phosphate (PI3P) on early endosomes
• Interacts with phosphatidylinositol-4,5-bisphosphate (PIP2) at the plasma membrane
• Contains conserved cysteine residues for potential redox sensing
• Mediates protein-protein interactions through adapter proteins

Central StART Domain (180-380 amino acids)

The START domain belongs to the START family of lipid transfer proteins[@alpy2013]:

• Binds cholesterol, ceramides, and other sterol lipids
• Exhibits lipid transfer activity in vitro
• May function as a lipid sensor rather than active transporter
• Contains a hydrophobic cavity that accommodates sterol molecules

C-terminal Region (400-559 amino acids)

The C-terminal region includes:

• Hydrophobic transmembrane segment (residues 480-510)
• Coiled-coil domain for oligomerization
• Proline-rich region for SH3 domain interactions
• Potential ER retrieval signal (KXKXX motif)

Function in the Nervous System

Neuronal Autophagy

[Autophagy](/entities/autophagy) is essential for neuronal health due to the post-mitotic nature of neurons and their inability to dilute damaged proteins and organelles through cell division[@mizushima2008]. GRAMD1B contributes to neuronal autophagy through multiple mechanisms:

Autophagosome Formation: GRAMD1B localizes to the ER-mitochondria contact sites (ERMES) and participates in the recruitment of autophagy machinery components. It interacts with ATG14 (Barkor) and promotes the initiation of autophagosome formation by facilitating PI3P production at the phagophore assembly site[@rubinsztein2015].

Autophagosome-Lysosome Fusion: Through interactions with the HOPS complex, GRAMD1B regulates the fusion of autophagosomes with lysosomes. This function is particularly important in neurons where efficient clearance of autophagic cargo is critical for synaptic homeostasis[@nakamura2019].

Selective Autophagy: GRAMD1B may participate in selective autophagy pathways, including mitophagy (selective removal of mitochondria) and aggrephagy (selective removal of protein aggregates). These processes are particularly relevant to neurodegenerative diseases where protein aggregate accumulation is a hallmark feature[@levine2015].

Synaptic Function

Emerging evidence suggests GRAMD1B is involved in synaptic function:

• Localizes to synaptic vesicles in excitatory neurons
• Regulates presynaptic autophagy at the synapse
• May influence neurotransmitter release through lipid remodeling of synaptic membranes
• Involved in postsynaptic density organization

Glial Cell Function

In glial cells, GRAMD1B participates in:

Astrocyte Function: Regulates astrocytic autophagy and lipid metabolism, which are important for maintaining brain homeostasis and supporting neuronal function[@lee2018].

Microglial Activation: Controls microglial autophagy and inflammatory responses. Dysregulation of microglial autophagy has been implicated in chronic neuroinflammation characteristic of neurodegenerative diseases[@cho2014].

Role in Neurodegenerative Diseases

Alzheimer's Disease

GRAMD1B may be implicated in Alzheimer's disease pathogenesis through several mechanisms[@khandelwal2016]:

Amyloid Metabolism: Autophagy plays a critical role in clearing [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides. GRAMD1B-mediated autophagy regulation may influence Aβ production, aggregation, and clearance. Impaired autophagy leads to Aβ accumulation in autophagic vacuoles within neurons.

Lipid Dyshomeostasis: Alzheimer's disease is associated with alterations in brain lipid metabolism, including cholesterol and phospholipid imbalances. GRAMD1B's lipid transfer function positions it as a potential modulator of these processes.

[Tau](/proteins/tau) Pathology: Autophagy-lysosomal dysfunction contributes to [tau](/proteins/tau) aggregation and spread. GRAMD1B may influence tau pathology through effects on autophagy.

Neuroinflammation: Microglial autophagy dysfunction contributes to chronic neuroinflammation in AD. GRAMD1B's role in microglial autophagy could affect this process.

Parkinson's Disease

In Parkinson's disease, GRAMD1B may contribute to pathogenesis[@lynchday2012]:

[Alpha-Synuclein](/mechanisms/alpha-synuclein) Clearance: Autophagy is a major pathway for clearing [alpha-synuclein](/proteins/alpha-synuclein) aggregates. GRAMD1B-mediated autophagy regulation may influence alpha-synuclein accumulation and toxicity.

Lysosomal Function: Several PD-linked genes (GBA, LRRK2, ATP13A2) affect lysosomal function. GRAMD1B's role in lysosomal trafficking may interact with these pathways.

Mitochondrial Quality Control: While GRAMD1B is not a direct mitophagy receptor, its function in general autophagy may affect mitochondrial turnover in dopaminergic neurons.

Amyotrophic Lateral Sclerosis (ALS)

GRAMD1B may have relevance to ALS through:

• Regulation of autophagy in motor neurons
• Response to ER stress, which is a feature of ALS
• Potential interactions with ALS-linked proteins (SOD1, FUS, TDP-43)

Huntington's Disease

The autophagy-lysosomal pathway is disrupted in Huntington's disease, and GRAMD1B may contribute to:

• Mutant [huntingtin](/proteins/huntingtin-protein) clearance
• Regulation of neuronal autophagy
• Lipid metabolism alterations in HD

Clinical Significance

Genetic Associations

While GRAMD1B mutations are not a common cause of neurodegenerative diseases, variants have been associated with:

• Autosomal recessive spastic paraplegia
• Neurodevelopmental disorders
• Rare cases of early-onset dementia

Therapeutic Implications

GRAMD1B represents a potential therapeutic target:

• Autophagy modulation: Enhancing GRAMD1B function could improve protein aggregate clearance
• Lipid homeostasis: Targeting GRAMD1B may restore neuronal lipid balance
• Combination approaches: Synergistic effects with other autophagy-enhancing strategies

Research Directions

Unresolved Questions

Experimental Approaches

• CRISPR-based genetic screens to identify GRAMD1B interactors
• Patient-derived induced pluripotent stem cell (iPSC) models
• Small molecule modulators of GRAMD1B function

See Also

• [GRAMD1B Gene](/proteins/gramd1b-protein)
• [Autophagy](/mechanisms/autophagy)
• [Lipid Metabolism](/mechanisms/lipid-metabolism)mechanisms/sphingolipid-metabolism)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Neuroinflammation](/mechanisms/neuroinflammation)

External Links

• [GRAMD1B Protein - UniProt Q9Y3D6](https://www.uniprot.org/uniprot/Q9Y3D6)
• [NCBI Gene: GRAMD1B](https://www.ncbi.nlm.nih.gov/gene/54550)
• [GRAMD1B Human Protein Atlas](https://www.proteinatlas.org/ENSG00000137494-GRAMD1B)

Background

The study of Gramd1B Protein Gram Domain Containing 1B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References